Related by context. All words. (Click for frequent words.) 79 tezampanel 73 tezampanel NGX# 72 oral prodrug 72 PRX # 71 Ophena TM 70 PXD# 70 Phenoptin 70 bicifadine 69 cannabinor 69 R#/MEM # 69 forodesine 69 Phase 2a 69 phase IIa clinical 69 Phase 2a clinical 69 INCB# [001] 69 Phase Ib study 68 Phase IIa 68 Traficet EN 68 Phase 1b trial 68 alvespimycin 68 ganetespib 68 JAK inhibitor 68 Phase IIa trial 68 Sym# 68 adipiplon 68 GAMMAGARD 68 LEP ETU 67 Tyrima 67 SILENOR TM 67 Elagolix 67 selective androgen receptor modulator 67 OXi# 67 CR# vcMMAE 67 INT# [002] 67 Phase IIb trials 67 DR Cysteamine 67 Phase 2a trial 67 vidofludimus 67 Phase IIa trials 67 MAP# 67 PEG PAL 67 Archexin 67 Bicifadine 67 Phase Ib 67 Phase IIa clinical 67 diabetic neuropathic pain 66 AeroLEF TM 66 otelixizumab 66 HGS ETR1 66 KRN# 66 CORT # 66 BEMA Buprenorphine 66 Panzem R 66 TOCOSOL Paclitaxel 66 MGCD# [001] 66 mGluR5 negative 66 CCR9 antagonist 66 Phase 2b study 66 HGS# 66 ELADUR 66 LY# [003] 66 generation purine nucleoside 66 GALNS 66 phase IIb clinical 66 velafermin 66 Tezampanel 66 TELINTRA 66 lomitapide 66 ADX# 66 INCB# [002] 66 Capesaris 66 Serdaxin 66 deforolimus 66 Azedra 66 ISIS # 66 DDP# 66 eltrombopag 66 metaglidasen 66 PRTX 66 PROMACTA 66 OMNARIS HFA 66 MAGE A3 ASCI 65 tanespimycin 65 oral formulation 65 ruxolitinib 65 class mGluR5 inhibitor 65 alvimopan 65 evaluating tivozanib 65 Synavive 65 pseudobulbar affect PBA 65 AP# [003] 65 confirmatory Phase III 65 Panzem R NCD 65 NVA# 65 Golimumab 65 KNS # 65 GLYX 65 PS# [001] 65 intranasal formulation 65 Relivar 65 HuMax EGFr 65 Exelixis compounds 65 CRx 65 obatoclax 65 huC# DM4 65 incyclinide 65 TRIOLEX 65 iSONEP 65 preclinical studies 65 SARMs 65 AZILECT R 65 Marqibo 65 PRT# 65 AEG# 65 elagolix 65 RGB # 65 CCX# 65 tiapamil 65 OncoVEX GM CSF 65 ELND# 65 liposomal formulation 65 Q#IR 65 Phase 2b clinical 65 Clonicel 64 Plicera 64 virus HCV protease inhibitor 64 ICA # 64 oral ridaforolimus 64 AZX# 64 Azixa 64 Mipomersen 64 Phase 1a clinical 64 Pimavanserin 64 zileuton 64 Neurodex 64 torezolid phosphate 64 allosteric modulator NAM 64 omega interferon 64 JAK2 inhibitor 64 preclinically 64 orally bioavailable 64 RSD# 64 Stedivaze 64 HGS ETR2 64 PNP inhibitor 64 PEG SN# 64 NP2 Enkephalin 64 GATTEX 64 XL# anticancer compounds 64 phase IIb 64 rHuPH# 64 TriRima 64 enzastaurin 64 PD LID 64 dyskinesia PD LID 64 Vilazodone 64 APOPTONE 64 BCX# 64 eniluracil 64 ALVESCO HFA 64 PDE4 inhibitor 64 elotuzumab 64 cystinosis patients 64 Frova ® 64 EOquin 64 CA4P 64 ENMD # 64 PREOS 64 BAY #-# 64 Zenvia ™ 64 Phase 2a clinical trials 64 placebo controlled clinical 64 Phase Ib clinical trials 64 lesinurad 64 urocortin 2 64 octreotide implant 64 pharmacodynamic effects 64 opioid induced bowel dysfunction 64 ZYBRESTAT 64 Serdaxin ® 64 HuMax CD# 64 ProSavin 64 pharmacodynamic PD 64 Zenvia TM 64 CoFactor 64 Chemophase 64 pharmacodynamic profile 64 octreotide acetate 64 maximally tolerated dose 64 Nasulin 64 Bezielle 64 Valortim 63 XmAb# 63 BEMA TM LA 63 docetaxel Taxotere ® 63 rNAPc2 63 subcutaneous formulation 63 Imprime PGG 63 DAVANAT 63 ARIKACE 63 investigational humanized monoclonal antibody 63 MEK inhibitor 63 ABILIFY ® 63 2 methoxyestradiol 63 EDEMA3 trial 63 ularitide 63 Triolex 63 tecarfarin 63 QVA# 63 angiogenesis inhibitor 63 RDEA# 63 vilazodone 63 novel VDA molecule 63 Parkinson disease levodopa induced 63 Zelrix 63 custirsen 63 uric acid lowering 63 orally administered inhibitor 63 entinostat 63 XP# XP# 63 M6G 63 CRLX# 63 pharmacodynamic 63 serotonin norepinephrine reuptake inhibitor 63 axitinib 63 ulimorelin 63 Preclinical studies suggest 63 refractory gout 63 Oracea TM 63 peripherally acting 63 rFIXFc 63 pharmacokinetic profile 63 Phase Ib clinical 63 atacicept 63 SNRI 63 pharmacodynamic properties 63 phase IIa 63 Allovectin 7 R 63 R#/MEM 63 systemically administered 63 HCD# [002] 63 IL# PE#QQR 63 PEG Interferon lambda 63 Arikace 63 calcitonin 63 ospemifene 63 LEVADEX 63 pradefovir 63 Ceflatonin 63 TACI Ig 63 AzaSite Plus 63 HuLuc# 63 ASONEP 63 aplindore 63 HuMax CD4 63 PSN# [002] 63 mGluR2 positive 63 ALN TTR# 63 Cleviprex TM clevidipine 63 Azedra TM 63 6R BH4 63 PEGylated anti 63 GSK# [001] 63 phase 2a 63 EpiCept NP 1 63 denufosol 63 GRN# 63 investigational compound 63 HspE7 63 teduglutide 63 inhaled formulation 63 Phase 1b 63 TOLAMBA 63 TBC# 63 XL# XL# XL# 63 favorable pharmacokinetic profile 63 nalbuphine ER 63 LymphoStat B 63 Perforomist ™ Inhalation Solution 63 LibiGel ® 63 ALN PCS 63 Safinamide 63 subcutaneously administered 63 oxymorphone ER 63 ALGRX 63 lintuzumab 63 INCB# [003] 63 administered subcutaneously 63 Chrysalin 63 pertuzumab 63 fosbretabulin 63 mertansine 63 MDV# 63 Androxal TM 63 safinamide 63 volociximab 63 Zingo TM 63 Phase 2b trial 63 ZOLINZA 62 Cloretazine R VNP#M 62 LE SN# 62 docetaxel Taxotere R 62 Perifosine 62 Amplimexon 62 Octreolin 62 CBLC# 62 ocrelizumab 62 ostarine 62 HCV protease inhibitor 62 IDX# 62 Phase IIb 62 Linaclotide 62 Symadex 62 ONTAK 62 visilizumab 62 SILENOR 62 LymphoStat B TM 62 dacetuzumab 62 preclinical 62 MoxDuo 62 phase Ib 62 JAK inhibitors 62 Locteron 62 CIPN 62 IAP inhibitor 62 TNF Tumor Necrosis Factor 62 Excellarate TM 62 FROVA 62 Seliciclib 62 methylnaltrexone 62 CDK inhibitor 62 Dyloject TM 62 anti amnesic 62 bevirimat 62 bortezomib Velcade 62 Pralatrexate 62 Trofex 62 Tesetaxel 62 MEK inhibitors 62 selective modulator 62 TG# [003] 62 oral bioavailability 62 Amigal 62 ocular formulation 62 teriflunomide 62 LY# [002] 62 Apoptone 62 Perforomist TM Inhalation Solution 62 SRT# [003] 62 Genz # 62 GAP #B# 62 dextromethorphan quinidine 62 pegylated interferons 62 Hsp# Inhibitor 62 BRIM2 62 Hsp# inhibitors 62 CD# CEA 62 LEVADEX TM 62 CINQUIL 62 Anturol TM 62 XL# XL# XL# XL# 62 RSD# oral 62 talactoferrin 62 FOLOTYN ® 62 eprotirome 62 Phase IIb clinical trials 62 Gabapentin GR 62 Bendavia 62 registrational 62 Dual Opioid 62 arzoxifene 62 candidate Zenvia 62 Aclidinium 62 CEQ# 62 Zerenex 62 investigational monoclonal antibody 62 RG# [001] 62 T Pred 62 ENTEREG ® 62 vascular disrupting agent 62 linaclotide 62 AEGR 62 REOLYSIN ® 62 febuxostat 62 Phase 2b clinical trials 62 Milnacipran 62 Tanespimycin 62 mipomersen 62 compound INCB# 62 YONDELIS 62 aldehyde dehydrogenase ALDH2 deficiency 62 VEGF inhibitor 62 IPL# 62 Dapagliflozin 62 tolerability profile 62 SAR# [002] 62 ALN TTR 62 proteasome inhibitor 62 proprietary transdermal patch 62 DexaSite 62 Entereg R 62 mGluR5 NAM 62 Romidepsin 62 Solazed TM 62 Menerba 62 TMC# [002] 62 Phase #b/#a trial 62 cediranib 62 oral picoplatin 62 Personalized Immunotherapy 62 synthetic retinoid 62 Onalta 62 BEMA TM Fentanyl 62 Xanafide 62 belinostat 62 ARIKACE ™ 62 Icatibant 62 Cannabinor 62 dexpramipexole 62 rasagiline tablets 62 Serada 62 RhuDex ® 62 sodium glucose cotransporter 62 Interferon alpha 62 efficacy tolerability 62 cariprazine 62 VA# [002] 62 ATL# [001] 62 Civacir 62 AVE# 61 DB# [003] 61 pharmacokinetics PK 61 bardoxolone methyl 61 CG# [003] 61 Dextofisopam 61 trospium 61 Phase IIb trial 61 phase IIb study 61 long acting muscarinic 61 Cethrin 61 tasimelteon 61 AZILECT ® 61 Tamibarotene 61 PRISTIQ 61 dirucotide 61 EXPAREL TM 61 SAR# [004] 61 riociguat 61 RAV# 61 Fx #A 61 pharmacokinetic PK study 61 Alocrest 61 dosing regimens 61 analgesic efficacy 61 ozarelix 61 forodesine hydrochloride 61 DU #b 61 Iloperidone 61 ponatinib 61 Generx 61 Factor VIIa 61 ILLUMINATE 61 cancer neuroendocrine tumor 61 humanized anti 61 #ME# 61 GnRH antagonist 61 Silodosin 61 Anavex #-# 61 EOquin TM 61 oral taxane 61 OMNARIS Nasal Spray 61 PI3K/Akt pathway inhibitor 61 epothilone 61 oral rivaroxaban 61 treprostinil 61 Omacetaxine 61 LEVADEX ™ 61 BNC# 61 eculizumab 61 Phase IIb clinical 61 SCH # 61 Phase IIa clinical trials 61 acyclovir Lauriad R 61 laquinimod 61 AZD# 61 PEGylated Fab fragment 61 valopicitabine 61 Phase IIIb clinical 61 IAP inhibitors 61 Xibrom TM 61 Microplasmin 61 BioVant 61 CDP# 61 TRANSDUR Sufentanil 61 induced macular edema 61 hepatitis C protease inhibitor 61 TAFA# 61 TREANDA 61 ATL# [002] 61 FOLFOX6 chemotherapy regimen 61 injectable depot 61 intranasal insulin 61 CYT# potent vascular disrupting 61 receptor tyrosine kinase inhibitor 61 delafloxacin 61 CTAP# Capsules 61 Guanilib 61 IIa trial 61 oral nucleoside analogue 61 Delta opioid receptor 61 small molecule defensin 61 Enhanze Technology 61 DURECT proprietary 61 faropenem 61 PF # [001] 61 LE DT 61 lurasidone 61 Zensana TM 61 novel oral anticoagulant 61 AAG geldanamycin analog 61 Phase 2b 61 ADAGIO study 61 Virulizin ® 61 ACAPODENE 61 pharmacokinetic properties 61 cysteamine 61 XL# [003] 61 MLN# 61 MERLIN TIMI 61 Altastaph 61 Ereska 61 CIMZIA R 61 Clolar ® 61 Carfilzomib 61 ramelteon 61 NasalFent 61 EZN 61 anticancer agent 61 vorinostat 61 Saforis 61 oral salmon calcitonin 61 MAXY alpha 61 Aurora kinase inhibitor 61 SAPHRIS 61 somatostatin analogue 61 Novolimus 61 Alzhemed TM 61 QLT# 61 Dasatinib 61 adenosine injection 61 CorVue ™ 61 Spiegelmer ® 61 neuroprotective properties 61 Asentar 61 hormone LHRH antagonist 61 Pivotal Phase III 61 O PPDS 61 HMG CoA reductase inhibitors 61 baminercept 61 Phase Ia 61 radiation sensitizer 61 ORENCIA R 61 OncoVEX 61 NUVIGIL 61 OvaRex ® MAb 61 GMX# 61 ACTEMRA TM 61 ALN RSV# 61 randomized Phase IIb 61 LUVENIQ 61 anticancer compound 61 TYKERB 61 CIMZIA TM 61 posaconazole 61 Phase 1b clinical 61 GLPG# 61 VELCADE melphalan 61 Besivance 61 Debio 61 S/GSK# 61 SNT MC# 61 cobiprostone 61 registrational trial 61 ONCONASE 61 EVIZON 61 OHR/AVR# 61 hyperphenylalaninemia HPA due 61 Oral NKTR 61 EGS# 61 TRO# 61 torsemide ER 61 Aurexis 61 velafermin belinostat 61 decitabine 61 DermaVir Patch 61 OvaRex R 61 Inhalation Solution 61 UPLYSO 61 selective A2A adenosine receptor 61 novel anticancer 61 dextofisopam 61 Zoraxel 61 Zenvia 61 pralatrexate 61 EP #R 61 sapacitabine 61 Rebif ® 61 brivaracetam 61 ascending doses 60 topical NSAID 60 IV APAP 60 HSP# inhibitor 60 multiple ascending dose 60 TELCYTA 60 Glufosfamide 60 diarrhea predominant irritable 60 trial evaluating PRX# 60 perampanel 60 ATL/TV# 60 Panzem 60 CYC# 60 SinuNase 60 Phase 2b Clinical Trial 60 Memryte 60 XL# XL# 60 Laquinimod 60 injectable formulation 60 iroxanadine 60 pharmacokinetic PK 60 tasocitinib 60 APD# 60 Targeted Chemotherapy 60 atrasentan 60 Phase IIB 60 PHX# 60 NEBIDO 60 disease modifying 60 Surfaxin LS 60 Adlea 60 dexanabinol 60 Nanobody 60 molecular imaging radiopharmaceutical 60 MAXY G# 60 initiate Phase 1b 60 migraine prophylaxis 60 immune modulatory 60 5 HT3 antagonist 60 Corlux 60 luteinizing hormone releasing 60 MoxDuo IR 60 DXL# 60 PolyActive ® 60 ZD# [001] 60 fostamatinib 60 ALN VSP 60 p# inhibitor 60 dose escalation Phase 60 sorafenib Nexavar 60 IND enabling 60 dosage regimens 60 antiangiogenic activity 60 Hsp# inhibitor 60 albinterferon alfa 2b 60 FM VP4 60 xanthine oxidase inhibitor 60 intranasal delivery 60 Lixivaptan 60 ® natalizumab 60 tafamidis 60 SLx 60 telbivudine 60 TKM ApoB 60 generation antisense 60 CTA# Injection 60 PLK1 SNALP 60 ALTROPANE 60 CYCLOSET 60 subcutaneous Herceptin 60 Azedra ™ 60 glufosfamide 60 MBP# [001] 60 TH# [003] 60 reslizumab 60 Aganocide 60 Denufosol 60 MEK inhibitor RDEA# 60 CB2 selective receptor agonist 60 VAPRISOL 60 nonclinical studies 60 PSMA ADC 60 NPSP# 60 EDEMA3 60 plasma kallikrein inhibitor 60 CCX# B 60 nucleoside analog 60 nucleotide analog 60 IMC A# 60 DASISION 60 mGluR2 NAM 60 candidate CRLX# 60 vosaroxin 60 administered intranasally 60 ESBA# 60 OncoGel 60 Gemzar ® 60 targeted radiotherapeutic 60 mirtazapine 60 Ostarine 60 MYDICAR ® 60 Phase #b/#a 60 blinded randomized placebo controlled 60 renin inhibitor 60 Tarvacin TM 60 PCK# 60 Darusentan 60 Tekamlo 60 Trizytek 60 corticotropin injection 60 transdermal spray 60 neratinib 60 NMDA antagonist 60 CD# antibody [001] 60 albiglutide 60 oral methylnaltrexone 60 Sapacitabine 60 ixabepilone 60 BENLYSTA ® 60 LHRH antagonist 60 RLY# 60 R roscovitine 60 RAPAFLO 60 Dacogen injection 60 CIMZIA ™ 60 Zemiva ™ 60 Fibrillex TM 60 Tasimelteon 60 proton pump inhibitor PPI 60 regorafenib 60 oral transmucosal 60 IRX 2 60 immunotherapeutic agent 60 Bortezomib 60 CCR5 antagonist 60 dimebon latrepirdine 60 acetonide FA 60 Ocrelizumab 60 ganaxolone 60 preclinical efficacy 60 anti emetic therapy 60 ridaforolimus 60 Homspera 60 dose limiting toxicities 60 Marqibo TM 60 Viramidine 60 urate lowering 60 PTH analogue 60 L BLP# 60 catheter occlusion 60 HCV protease inhibitors 60 Ketotransdel TM 60 TPI ASM8 60 HZT 60 limiting toxicity 60 zileuton CR 60 HepeX B 60 ELACYT 60 ImmunoVEX HSV2 60 Luveniq 60 bifeprunox 60 Targretin 60 Aerosurf 60 NNR Therapeutics 60 Genasense ® oblimersen 60 AVN# [001] 60 cMET 60 basal insulin analogue 60 Androxal 60 VEGF Trap 60 cilengitide 60 pharmacokinetic studies 60 INC# 60 SERMs 60 cangrelor 60 Phase IIb Trial 60 phase IIb trial 60 Zysolin TM 60 Kuvan R 60 defensin mimetic antibiotic 60 oral gallium 60 Urocidin 60 HCV polymerase inhibitors 60 Xeloda ® 60 GED aPC 60 carfilzomib 60 sitaxsentan 60 OMP #M# 60 Ketotransdel ® 60 ATD Gel 60 sd rxRNA compounds 60 multi kinase inhibitor 60 allosteric modulator PAM 60 NU# [001] 60 EDEMA4 60 unique alkylating agent 60 Pivotal Phase 60 investigational drug 60 Omacetaxine mepesuccinate 60 nebulized formoterol fumarate 60 HQK 60 Cetrorelix 60 intravenously administered 60 tolerability 60 Ophena 60 palonosetron 60 Zemplar Capsules 60 DuraSite 60 galiximab 60 muraglitazar 60 histone deacetylase HDAC inhibitor 60 Technosphere Insulin 60 PDE4 inhibitors 60 Frova R 60 granisetron 60 FASLODEX 60 ANAVEX #-# [003] 60 Cyclooxygenase Inhibiting Nitric Oxide 60 APTIVUS r 60 HCV protease 60 betrixaban 60 sodium Injection 60 plus Copegus R 59 nasal antihistamine 59 apremilast 59 Hsp# inhibition 59 Prodarsan ® 59 Meets Primary Endpoint 59 pharmacokinetic PK profile 59 ISTODAX 59 bosutinib 59 danoprevir 59 rALLy 59 Rasagiline 59 Catena ® 59 LymphoStat B belimumab 59 AMR# 59 Prestara 59 Trofex TM 59 ISENTRESS 59 trodusquemine 59 TKB# 59 HGS ETR1 mapatumumab 59 IMPDH inhibitor 59 TLK# 59 celgosivir 59 Cimzia R 59 Phase III Clinical Trial 59 anti arrhythmic 59 tiotropium bromide 59 generation proteasome inhibitor 59 radezolid 59 TRANSDUR ® 59 nitazoxanide 59 non nucleoside inhibitor 59 ALKS 59 insulin sensitizing 59 Phase 1a 59 BCR ABL inhibitors 59 Ixabepilone 59 Tarceva TM 59 GLP toxicology studies 59 adecatumumab 59 Linjeta TM 59 JAK1 59 Ventavis 59 Fortical R 59 Zalbin 59 schizophrenia CIAS 59 RNAi therapeutic targeting PCSK9 59 Phase #/#a trial 59 budiodarone 59 Squalamine 59 Combunox 59 JANUVIA 59 Intraject 59 ANYARA 59 Hyphanox 59 MOZOBIL 59 bendamustine 59 dimebon 59 seliciclib 59 MNTX 59 tivozanib 59 lucinactant 59 erlotinib Tarceva ® 59 PrevOnco 59 Panzem NCD 59 inecalcitol 59 Phase III trials 59 Proquin XR 59 Onconase 59 SinuNase ™ 59 LHRH antagonists 59 GFT# 59 DP b# 59 PBT2 59 Phase III clinical 59 BEMA Granisetron 59 pomalidomide 59 tesetaxel 59 viral kinetics 59 Androxal ® 59 IMA# 59 ARC# [002] 59 dexamethasone Decadron 59 Forodesine HCl 59 nab paclitaxel 59 liprotamase 59 generation Hsp# inhibitor 59 CORLUX 59 Epanova 59 BAL# [002] 59 squalamine 59 Clevudine 59 systemic immunosuppressive drugs 59 epigenetic therapies 59 MEND CABG II 59 sorafenib tablets 59 cetuximab Erbitux 59 ThGRF 59 EMBEDA ™ 59 PI3K inhibitor 59 PEGPH# 59 RH1 59 seliciclib CYC# 59 LB# [003] 59 ALD# 59 SILENOR ™ 59 AGILECT R 59 markets Gelclair R 59 perifosine 59 lubiprostone 59 Tavocept 59 post herpetic neuralgia PHN 59 telcagepant 59 ACTEMRA 59 Anthim 59 Vidaza azacitidine 59 VEGF inhibitors 59 GV# [001] 59 Anticalin R 59 SinuNase TM 59 omecamtiv mecarbil 59 Firazyr 59 potent CYP#A# inhibitors 59 favorable tolerability 59 placebo controlled Phase 59 Amphotericin B 59 tocilizumab 59 oral FTY# 59 ropinirole Requip 59 veltuzumab 59 pharmacokinetic equivalence 59 pleconaril 59 Alfimeprase 59 Cellegesic 59 CLORETAZINE TM VNP#M 59 orally dosed 59 THR beta agonist 59 Troxatyl 59 fenretinide 59 AQ4N 59 rxRNA 59 selective estrogen receptor 59 Protexia R 59 PREZISTA r 59 therapeutic monoclonal antibody 59 LATUDA 59 Fampridine SR 59 GEM OS2 59 Sanctura XR 59 NUEDEXTA 59 coadministration 59 Quinamed 59 dose cohort 59 IoGen 59 antiplatelet agent 59 Preclinical studies 59 biologic therapy 59 Probuphine 59 Acetavance 59 Plenaxis TM 59 Voreloxin 59 Eltrombopag 59 confirmatory Phase 3 59 USL# 59 leading oral taxane 59 GLP1 agonist 59 PDX pralatrexate 59 AMEVIVE